



MEDICAMEN BIOTECH LIMITED

CIN: L74899DL1993PLC056594

Registered Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi – 110019, India

Email: cs@medicamen.com | **Website:** www.medicamen.com

CORRIGENDUM TO THE NOTICE TO SHAREHOLDERS

Medicamen Biotech Limited had issued a Notice dated February 26, 2025, for seeking approval of members for certain agenda items through the Extra-Ordinary General Meeting (“EGM”). The EGM Notice has already been circulated to all the Shareholders of the Company in due compliance with the provisions of the Companies Act, 2013 read with rules made thereunder.

The Company through this communication wishes to bring to the notice of the Shareholders, the following changes in the said EGM Notice:

Changes to the Explanatory Statement to Item No. 1 and 2:

Point No. I of the Explanatory Statement to the EGM Notice shall be substituted and read as under:

Objects of the Preferential Issue:

1. In the heading of object number b): the word “etc.” has been deleted.

The revised heading of object number b) is read as under:

b) Registration of dossiers:

2. In the heading of object number d): the words “in some area of upgradation” has been deleted.

The revised heading of object number b) is read as under:

d) Capital expenditure of the existing facilities:

3. The subpoint (3) of object number e) **Expansion of operations in Domestic Market** stating *Increased participation in domestic medical conferences to enhance brand recognition and engagement with healthcare professionals* has been deleted.

Accordingly, in the table mentioned under the heading **Utilization of Proceeds**, the said headings at point 2 and 4 shall be read as:

2. Registration of dossiers
4. Capital expenditure of the existing facilities.

All other particulars and details remain unchanged. The corrigendum shall be read in conjunction with the Notice of Extra-Ordinary General Meeting dated February 26, 2025, together with an explanatory statement. This corrigendum is also available on the Company's website at www.medicamen.com, and on the website of the National Stock Exchange of India Limited ("NSE") at www.nseindia.com and BSE Limited at www.bseindia.com ("BSE") and on the website of Company's Registrar and Transfer Agent, MUFGE Intime India Private Limited ("MIPL") at www.in.mpms.mufg.com. The corrigendum shall also be sent electronically to all the registered shareholders of the Company.

Thanking you,

Yours faithfully,

For Medicamen Biotech Limited

Ms. Parul Choudhary

Company Secretary & Compliance Officer

Place: New Delhi

Date: March 20, 2025